Clinical Trial Update: Sunitinib to Treat Recurrent Brain Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of sunitinib for recurrent brain cancer (glioblastoma, malignant glioma, and anaplastic glioma) was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Glioma
• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma Multiforme, Malignant Gliomas | Phase 2 | Status: TERMINATED | Results posted: 2013-06-25